My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Rocket Pharmaceuticals, Inc. - Common Stock (NQ:RCKT)

3.780 +0.040 (+1.07%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Rocket Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Patient Death In Rocket Pharma Trial Triggers Downgrades, But Retail Traders Bet Big On Strong Recovery ↗

May 28, 2025

Message volume on Stocktwits spiked to ‘extremely high’ levels, and the ticker added 20% more watchers.

Via Stocktwits

Topics Death

Here are the top movers in Tuesday's session. ↗

May 27, 2025

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

May 27, 2025

Via Benzinga

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

May 27, 2025

Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

Top 3 Health Care Stocks That Could Blast Off This Month ↗

January 06, 2025

Via Benzinga

Analyst Ratings for Rocket Pharmaceuticals ↗

November 07, 2023

Via Benzinga

Dow Surges Over 600 Points; US Durable Goods Orders Fall in April ↗

May 27, 2025

Via Benzinga

Topics Stocks

Rocket Pharma Reports Patient Death In Rare Disease Gene Therapy Trial, FDA Puts Clinical Hold ↗

May 27, 2025

Rocket Pharmaceuticals halted its Danon disease gene therapy trial after a patient death, with the FDA placing the study on clinical hold for review.

Via Benzinga

There are notable gap-ups and gap-downs in today's session. ↗

May 27, 2025

In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down.

Via Chartmill

Nasdaq Jumps Over 300 Points On EU Tariff Delay; AutoZone Posts Downbeat Earnings ↗

May 27, 2025

Via Benzinga

Rocket Pharmaceuticals Stock Drops Pre-Market After FDA Pauses Gene Therapy Trial Over Patient Death: Retail Turns Bullish ↗

May 27, 2025

Rocket Pharmaceuticals said that it is working with the FDA to ensure safety of all study patients and resume the trial “as expeditiously as possible."

Via Stocktwits

Stay updated with the stocks that are on the move in today's pre-market session. ↗

May 27, 2025

Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

May 27, 2025

Via Benzinga

Rocket Pharma's Gene Therapy Shows Promise in ACM Patients, Says Analyst ↗

May 16, 2025

Chardan's Geulah Livshits raises target price for RCKT to $46 and maintains Buy rating after promising data on gene therapy for heart disease.

Via Benzinga

Pentair To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Friday ↗

May 16, 2025

Via Benzinga

Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday ↗

April 21, 2025

Via Benzinga

3 Stocks Insiders Are Buying Rapidly Amid Market Volatility ↗

April 17, 2025

Despite market volatility, these stocks are seeing strong buys by insiders.

Via Talk Markets

Topics Stocks / Equities

Netflix, Ericsson, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Monday ↗

April 15, 2025

Via Benzinga

3 Small-Cap Stocks That Are Ready to Rocket Higher

November 27, 2024

With lower interest rates and lower corporate taxes more likely, it's a good time to consider three small-cap stocks that present a buying opportunity

Via MarketBeat

Topics Government

Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst ↗

November 19, 2024

Rocket Pharmaceuticals reveals RP-A501 Phase 1 data for Danon disease, showing durable efficacy, reduced cardiac biomarkers, and improved heart health.

Via Benzinga

Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday ↗

August 26, 2024

Via Benzinga

RCKT Stock Earnings: Rocket Pharmaceuticals Misses EPS for Q2 2024 ↗

August 05, 2024

RCKT stock results show that Rocket Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

FDA Rejects Rocket Pharmaceuticals' Gene Therapy For Rare Immune Disorder, Asks For More Data, Stock Slides ↗

June 28, 2024

Rocket Pharmaceuticals shares fell after the FDA issued a Complete Response Letter for Kresladi, a gene therapy for severe leukocyte adhesion deficiency-I. The FDA requested additional CMC...

Via Benzinga

Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

June 28, 2024

Via Benzinga

These 3 Clinical-Stage Biotech Stocks Can Offer Exponential Gains ↗

June 14, 2024

These biotech stocks, lacking in profitability but seeding huge potential, should be on your watchlist.

Via Talk Markets

RCKT Stock Earnings: Rocket Pharmaceuticals Beats EPS for Q1 2024 ↗

May 06, 2024

RCKT stock results show that Rocket Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

7 Speculative Stocks to Double Your Money THIS Year ↗

January 22, 2024

Although terribly risky, these stocks to double your money could be enticing if you have some pocket change lying around.

Via InvestorPlace

Merit Medical Systems And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

December 05, 2023

U.S. stock futures traded lower this morning, with the Dow Jones futures falling more than 40 points on Monday.

Via Benzinga

Topics Stocks

Rocket Pharmaceuticals Stock Sees Improved Price Strength ↗

November 02, 2023

On Thursday, Rocket Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 68 to 78

Via Investor's Business Daily

Rocket Pharmaceuticals Stock Sees RS Rating Pops Higher ↗

October 27, 2023

A Relative Strength Rating upgrade for Rocket Pharmaceuticals shows improving technical performance. Will it continue?

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.